Aptamers in the diagnosis and treatment of coronavirus (search done on 21 June 2020)
Citation: Torabi R, Ranjbar R, Halaji M, et al. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review. Molecular and cellular probes. 2020 Oct;53:101636.
What is this? COVID-19 is a novel infection and research into diagnostic features and possible treatments, such as aptamer-based biosensors and drugs, is important for policy makers.
In this rapid review, the authors searched for studies on the use of aptamers for the diagnosis and treatment of coronaviruses. They did not restrict their searches by date, type or language of publication and did the most recent search on 21 June 2020. They included 3 studies on diagnostic aptamers and 2 studies on therapeutic aptamers.
What was found: At the time of this review, the included studies suggested that aptamer molecules might be effective anti-coronavirus agents in both diagnosis and treatment.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.